EC
PRLD icon

EcoR1 Capital’s Prelude Therapeutics PRLD Stock Holding History

EcoR1 Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Buy
+947,049
New +$2.48M 0.14% 26
2023
Q4 		– Sell
-1,157,452
Closed -$3.58M – 54
2023
Q3 		$3.58M Hold
1,157,452
– – 0.12% 41
2023
Q2 		$5.21M Buy
+1,157,452
New +$6.92M 0.13% 40

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital's PRLD Position: Q1 2026 in Review

EcoR1 Capital opened a new position in Prelude Therapeutics (PRLD) in Q1 2026: 947,049 shares worth $3.24M. The stake represents 0.14% of the portfolio and ranks #26 among its holdings. This is a return to the name: EcoR1 Capital previously reported a position in PRLD as recently as Q3 2023.

EcoR1 Capital first reported a position in PRLD in Q2 2023 and has held it in 3 quarters since. The position peaked at $5.21M in Q2 2023. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • EcoR1 Capital held 947,049 shares of Prelude Therapeutics worth $3.24M as of Q1 2026.
  • Prelude Therapeutics was a new EcoR1 Capital position in Q1 2026.
  • Prelude Therapeutics made up 0.14% of EcoR1 Capital's portfolio in Q1 2026, its #26 holding.
  • EcoR1 Capital first reported a position in Prelude Therapeutics in Q2 2023 and has held it in 3 quarters since.
  • EcoR1 Capital's Prelude Therapeutics position peaked at $5.21M in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on EcoR1 Capital's 13F filing for Q1 2026, filed 15 May 2026.